Welcome to our dedicated page for Xtl Biopharmaceu news (Ticker: XTLB), a resource for investors and traders seeking the latest updates and insights on Xtl Biopharmaceu stock.
XTL Biopharmaceuticals Ltd. (XTLB) generates news across biopharmaceutical development, IP portfolio management, and technology-driven platforms. Company announcements describe XTL as an IP portfolio company with assets that include hCDR1 for lupus, the wholly owned web data AI subsidiary The Social Proxy, and a binding agreement to acquire a majority stake in NeuroNOS, a nitric oxide–focused platform for autism and neuro-oncology therapeutics.
News items for XTL commonly cover strategic transactions such as the acquisition of The Social Proxy and the planned acquisition of 85% of NeuroNOS. These releases outline how XTL expands its portfolio with high-potential, IP-based assets in areas like AI web data infrastructure and disease-modifying therapeutics for autism spectrum disorder and brain cancers. Updates also highlight the status of hCDR1, which XTL holds as an IP asset for lupus and, in some disclosures, Sjögren’s syndrome, and for which it seeks strategic collaborations.
Investors following XTLB news will also encounter corporate governance and regulatory updates, including changes in executive and board roles, shareholder meeting results, and Nasdaq notifications regarding minimum bid price compliance. These communications provide insight into how XTL manages its listing status on the Nasdaq Capital Market and Tel Aviv Stock Exchange.
For readers tracking developments in autism therapeutics, autoimmune IP, and AI web data platforms, XTL’s news feed offers a view into how the company assembles and steers its portfolio. Regular updates on transactions, orphan drug designations at NeuroNOS, and management changes help contextualize the evolution of XTL’s business and asset base.
XTL Biopharmaceuticals (Nasdaq: XTLB) said it is working to close the proposed acquisition of 85% of NeuroNOS from Beyond Air and has scheduled a shareholders meeting on Feb 17, 2026 to approve a private placement of up to US$2.0 million.
Management said the acquisition plus the private placement are intended to remedy a Nasdaq Listing Rule 5550(b)(1) deficiency by restoring the company to a minimum of $2,500,000 in stockholders’ equity, and XTL is preparing a Nasdaq plan to regain compliance. The company cautioned there is no assurance the transactions or Nasdaq approvals will occur.
XTL Biopharmaceuticals (Nasdaq:XTLB) received a Nasdaq letter dated January 20, 2026 notifying the company it does not meet Nasdaq Listing Rule 5550(b)(1) because stockholders' equity was a $47,000 deficit for the period ended June 30, 2025, below the $2,500,000 minimum.
The notification is not an immediate delisting and ADSs will continue to trade under XTLB. XTL has 45 days, until March 6, 2026, to submit a compliance plan; if accepted Nasdaq may grant up to 180 calendar days to evidence compliance. XTL says it is evaluating options and intends to try to regain compliance but gives no assurance it will succeed.
XTL Biopharmaceuticals (NASDAQ: XTLB) agreed to acquire 85% of NeuroNOS from Beyond Air, creating a focused autism and neuro‑oncology platform. Consideration includes 19.9% of XTL issued share capital, $1.0 million cash and up to $32.5 million in contingent milestones (development + commercial). NeuroNOS holds two FDA Orphan Drug designations (Phelan‑McDermid Syndrome and glioblastoma). Management/scientific leadership includes founder Prof. Haitham Amal and two Nobel Laureates, positioning XTL to advance preclinical programs targeting nitric oxide dysregulation in autism. Transaction remains subject to customary closing conditions and XTL shareholder approval.
XTL Biopharmaceuticals (Nasdaq:XTLB) received a Nasdaq notice dated December 22, 2025 informing the company that its 30-day closing bid price has fallen below the continued listing requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2).
The notice does not trigger immediate delisting and the company’s American Depositary Shares will continue trading under XTLB. XTL has a 180-calendar-day compliance period until June 22, 2026 to regain compliance by achieving a closing bid of at least $1.00 for 10 consecutive business days. If not regained, XTL may be eligible for an additional 180-day period by meeting market-value and other initial listing standards and notifying Nasdaq, potentially via a reverse stock split. XTL said it is evaluating options but gave no assurance of success.
XTL Biopharmaceuticals (Nasdaq: XTLB) has appointed Noam Band as its new Chief Executive Officer, while Shlomo Shalev continues as Chairman of the Board of Directors. Band brings significant experience from his previous roles, including serving as CEO and Chairman of Gix Internet and CEO of Dotomi.
Band holds an MBA and B.A. in Economics from The Hebrew University of Jerusalem. His background includes strategic business development, market expansion, and operational leadership positions. XTL currently operates through its wholly-owned subsidiary, The Social Proxy , a web data AI company developing an ethical proxy data extraction platform. The company also maintains a sublicensed IP portfolio for hCDR1 in Lupus treatment.
XTL Biopharmaceuticals (NASDAQ: XTLB) has completed the acquisition of THE SOCIAL PROXY , an AI web data company, expanding its IP portfolio. The transaction involved XTL acquiring all of Social Proxy's share capital in exchange for ADSs representing 44.6% of XTL's issued share capital and a $430,000 cash payment. Additionally, XTL completed a private placement of $1.5 million to support growth and financial needs.
Social Proxy will operate as a fully owned subsidiary of XTL, with its shareholders appointing two representatives to XTL's board of directors. This acquisition aligns with XTL's strategy to expand its asset portfolio in high-potential areas, particularly in the AI Web Data market. The move is expected to add significant value to XTL and its shareholders.
XTL Biopharmaceuticals announced a definitive agreement to acquire The Social Proxy, an AI web data company. The deal involves issuing shares equating to 44.6% of XTL's issued share capital and paying $430,000. The acquisition aims to enhance XTL's asset portfolio with high-potential assets. The Social Proxy will operate as a subsidiary, with its shareholders appointing two board members. The transaction includes a $1.5 million private placement approved by shareholders, subject to closing conditions. XTL aims to leverage The Social Proxy's advanced IP-based platform for AI and BI applications.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Xtl Biopharmaceu (XTLB)?
What is the market cap of Xtl Biopharmaceu (XTLB)?
